Independent Directors’ Report on Mitigating Risks Related to the Sale of Opioid Medications

Posted on November 30, 2018

Endo's Board of Directors (the Board) remains committed to transparency with its stakeholders, as well as conducting its business in accordance with all legal and regulatory requirements and with the highest standards of ethical behavior. Below is a report which discusses key elements related to Endo’s opioid business risks, including the Board’s general oversight and monitoring of Endo’s compliance program, litigation matters and lobbying activities; Endo’s voluntary opioid risk mitigation efforts; and, Endo’s historical and existing compliance measures.

Independent Directors’ Report